LDL-C Targets in Secondary Prevention: How Low Should We Go?
<h3>Abstract</h3><p dir="ltr">The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been w...
محفوظ في:
| المؤلف الرئيسي: | Karim Bayoumy (3496688) (author) |
|---|---|
| مؤلفون آخرون: | Mohammed Gaber (14151942) (author), Preethi Mani (14151945) (author), Rishi Puri (6090599) (author), Eoin Donnellan (12122073) (author), Leslie Cho (8859803) (author), Donald Clark (14151948) (author), Seth S. Martin (8164878) (author), Mohamed B. Elshazly (14151951) (author) |
| منشور في: |
2019
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
حسب: Nagham N. Hindi (18526815)
منشور في: (2021) -
The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype–Phenotype Correlations of the Disease
حسب: Amina Kamar (295977)
منشور في: (2021) -
The role of protective genetic variants in modulating epigenetic aging
حسب: Yosra Bejaoui (8552574)
منشور في: (2025) -
The new accounting standard IFRS 9 and its impact on how banks should provision for credit losses
حسب: ALBANNA, AMNA AHMAD
منشور في: (2019) -
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
حسب: Elysia M Alvarez (12229352)
منشور في: (2022)